As the merger between Bristol-Myers Squibb (BMY) and Celgene (CELG) approaches the finish line, investors face the surprising dilemma of how to handle Celgene trading at $110 as the merger is a day away from closing. Along with my previous recommendation, investors want to own BMY after the merger as the valuation remains cheap.
Image Source: Celgene website
Last Hurdle
Last Friday, Bristol-Myers confirmed the U.S. Federal Trade Commission accepted the consent order due to the divestment of OTEZLA allowing for the parties to close the Celgene merger. The companies